Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
Phase II trial of carboplatin/docetaxel in patients with resected NSCLC
Hidetaka Uramoto, Takeshi Hanagiri, Fumihiro Tanaka, Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan
Ryoichi Nakanishi, Department of Thoracic Surgery, Shin-Kokura Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Kokurakita-ku, Kitakyushu 803-0816, Japan
Akihiko Uchiyama, Department of Surgery, Kyushu Kouseinenkin Hospital, Kitakyushu 806-8501, Japan
Masaaki Inoue, Department of Chest Surgery, Shimonoseki City Hospital, Shimonoseki 750-8520, Japan
Masakazu Sugaya, Department of Chest Surgery, Chubu Rosai Hospital, Nagoya 455-0018, Japan
Teruo Iwata, Department of Thoracic Surgery, Niigata Rousai Hospital, Niigata 942-0071, Japan
Noriyuki Ebi, Department of Respiratory Medicine, Iizuka Hospital, Iizuka 820-8505, Japan
Author contributions: All the authors contributed to this work.
Supported by JPJS KAKENHI, No. 25462202; A UOEH Research Grant for Promotion of Occupational Health; Uramoto H, Hanagiri T and Tanaka F received a research grant that belongs to the institute from Sanofi -Aventis, Inc.
Correspondence to: Hidetaka Uramoto, MD, PhD, Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan. hidetaka@med.uoeh-u.ac.jp
Telephone: +81-93-6917442 Fax: +81-93-6924004
Received: October 31, 2013
Revised: February 15, 2014
Accepted: February 18, 2014
Published online: March 28, 2014
Processing time: 147 Days and 2.3 Hours
Revised: February 15, 2014
Accepted: February 18, 2014
Published online: March 28, 2014
Processing time: 147 Days and 2.3 Hours
Core Tip
Core tip: Adjuvant chemotherapy with a tri-weekly schedule of carboplatin and docetaxel was feasible in Japanese non-small cell lung cancer patients. In clinical practice, this regimen represents a potential treatment option that may be superior to other regimens. The main limitation associated with this study is the small number of patients enrolled. Therefore, it is important to employ a reference arm for any future randomized clinical trials evaluating this treatment regimen.